Medirom Converts ¥275M Bond into Secured Loan, Lifting Total Debt to ¥475M
MRM sits 20% above its 52-week low of $0.83 on light trading volume (0.2× avg).
Summary
Medirom refinanced a ¥275M convertible bond into a secured loan, raising total debt to ¥475M and pledging its subsidiary shares as collateral.
Key Events · Financing and Capital Events · MRM
-
Bond Refinanced into Secured Loan
The ¥275M convertible bond due June 30, 2026 was refinanced into a loan, increasing total principal to ¥475M (~$3.2M at current exchange rates).
-
Subsidiary Shares Pledged as Collateral
All shares of MEDIROM MOTHER Labs Inc. are now pledged to secure the full ¥475M obligation, giving the lender a first-priority security interest.
-
Loan Terms: 10% Interest, Due Dec 2026
The combined loan bears 10% annual interest and matures on December 31, 2026, with default interest provisions unchanged.
-
Financial Pressure Mounts
This restructuring follows a Nasdaq non-compliance notice and the complete exit of major shareholder Kufu Company Holdings, the lender in this agreement.
Analysis · MRM · Trade & Services
To avoid an immediate cash repayment, Medirom converted a maturing ¥275 million convertible bond into a secured loan, pushing total debt under the agreement to ¥475 million. The loan carries 10% interest and is due December 31, 2026. As part of the restructuring, the company pledged all shares of its subsidiary MEDIROM MOTHER Labs as collateral. While this buys time, it increases secured debt and encumbers a key asset, heightening financial risk against a backdrop of Nasdaq non-compliance and a recent major shareholder exit.
At the time of this filing, MRM was trading at $1.00 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $7.2M. The 52-week trading range was $0.83 to $4.45. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.